<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cutaneous leishmaniasis: Treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cutaneous leishmaniasis: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cutaneous leishmaniasis: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Naomi Aronson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3503298"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Leishmaniasis consists of a complex of vector-borne diseases caused by a heterogeneous group of protozoa belonging to the genus <em>Leishmania</em>; it is transmitted by sand fly vectors [<a href="#rid1">1</a>]. There is a broad array of clinical leishmaniasis syndromes; among these, the clinical course, treatment options, response to therapy, and prognosis are all highly variable. Treatment choices are complicated by the paucity of well-controlled comparative trials and lack of standardized outcome measures [<a href="#rid2">2,3</a>]. </p><p>Old World cutaneous leishmaniasis (CL) consists mainly of <em>L.L. major</em> and <em>L.L. tropica</em>. Less common species include <em>L.L. infantum</em> and <em>L.L. aethiopica</em>  (<a class="graphic graphic_table graphicRef86988" href="/z/d/graphic/86988.html" rel="external">table 1</a>). New World CL consists mainly of <em>L.L. mexicana</em>, <em>L.L. amazonensis</em>, and <em>Viannia</em> subgenus  (<a class="graphic graphic_table graphicRef86988" href="/z/d/graphic/86988.html" rel="external">table 1</a>). The <em>Leishmania</em> subgenus<em> Mundinia</em> has been described in areas typically not considered endemic for leishmaniasis, such as Thailand, Myanmar, Ghana, and the Caribbean [<a href="#rid4">4</a>]. Of these <em>Leishmania</em> species, infection due to <em>L.V. braziliensis, L.V. panamensis,</em> and <em>L.V. guyanensis</em> are considered complicated due to risk for mucosal leishmaniasis (ML), although other species can cause ML as well. (See  <a class="medical medical_review" href="/z/d/html/5689.html" rel="external">"Cutaneous leishmaniasis: Clinical manifestations and diagnosis"</a>.)</p><p>The treatment of CL and ML is reviewed here. The clinical features, diagnosis, epidemiology, and control are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5689.html" rel="external">"Cutaneous leishmaniasis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/87186.html" rel="external">"Cutaneous leishmaniasis: Epidemiology and control"</a>.)</p><p class="headingAnchor" id="H5914229"><span class="h1">CUTANEOUS LEISHMANIASIS</span></p><p class="headingAnchor" id="H4273845"><span class="h2">Clinical approach</span></p><p class="headingAnchor" id="H2793911"><span class="h3">Uncomplicated versus complicated infection</span><span class="headingEndMark"> — </span>The approach to management of cutaneous leishmaniasis (CL) begins with establishing the clinical severity of infection.</p><p>Features of uncomplicated CL include [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Infection with species not likely to be associated with mucosal leishmaniasis (ML)</p><p class="bulletIndent1"><span class="glyph">●</span>No mucosal involvement</p><p class="bulletIndent1"><span class="glyph">●</span>Single lesion or a few lesions</p><p class="bulletIndent1"><span class="glyph">●</span>Small lesion size (eg, &lt;1 cm)</p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompetent host</p><p></p><p>Features of complicated CL include [<a href="#rid1">1,5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Infection with species associated with ML (primarily <em>Viannia</em> subgenus, especially in the "mucosal belt" of Bolivia, Peru, and Brazil)</p><p class="bulletIndent1"><span class="glyph">●</span>More than four lesions of significant size (eg, &gt;1 cm)</p><p class="bulletIndent1"><span class="glyph">●</span>Individual lesions ≥5 cm</p><p class="bulletIndent1"><span class="glyph">●</span>Subcutaneous nodules</p><p class="bulletIndent1"><span class="glyph">●</span>Regional adenopathy &gt;1 cm size (somewhat controversial)</p><p class="bulletIndent1"><span class="glyph">●</span>Size or location of lesions for which local treatment is not feasible</p><p class="bulletIndent1"><span class="glyph">●</span>Lesions on face, fingers, toes, or genitalia</p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppressed host</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical failure of local therapy after two to three months posttreatment</p><p></p><p>Forms of CL that should be managed as complicated infection with expert consultation include:</p><p class="bulletIndent1"><span class="glyph">●</span>Leishmaniasis recidivans (due to <em>L.L. tropica</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated CL (due to <em>L.V. braziliensis</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse CL (due to <em>L.L. mexicana</em>, <em>L.L. amazonensis, or L.L. aethiopica</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>Infections due to <em>L.L. aethiopica </em>[<a href="#rid6">6</a>]</p><p></p><p class="headingAnchor" id="H113484778"><span class="h3">Whom to treat</span><span class="headingEndMark"> — </span>The objective of CL treatment is clinical cure not parasitologic cure. Many CL infections eventually resolve clinically without treatment, and not all patients who undergo treatment demonstrate elimination of parasitic infection [<a href="#rid7">7</a>]. Treatment decisions must include consideration of individual risks and benefits (which can be complex given the large number of parasite species with variable clinical syndromes), complications, rates of spontaneous resolution, and patient preference [<a href="#rid8">8</a>]. CL in children is common, but most clinical trial data derives from treatment of adults [<a href="#rid9">9,10</a>]. (See <a class="local">'Uncomplicated versus complicated infection'</a> above and  <a class="medical medical_review" href="/z/d/html/5689.html" rel="external">"Cutaneous leishmaniasis: Clinical manifestations and diagnosis"</a>.)</p><p>Clinical observation (in the absence of treatment) is reasonable for immunocompetent patients with uncomplicated lesions that are healing spontaneously whose infection is either known to be caused by a <em>Leishmania</em> species not associated with increased risk for ML <strong>or</strong> whose species is unknown but whose infection was acquired outside of areas with <em>Leishmania</em> species associated with increased risk for ML  (<a class="graphic graphic_table graphicRef86988" href="/z/d/graphic/86988.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef110869" href="/z/d/graphic/110869.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>]. The decision to pursue this approach should be made in conjunction with patient involvement. Reconsideration of treatment is warranted for patients managed with clinical observation who do not heal in four to six weeks. (See <a class="local">'Assessing risk for mucosal disease'</a> below and <a class="local">'Clinical follow-up'</a> below.)</p><p>Local therapy is reasonable for patients with uncomplicated CL who are not already healing spontaneously and/or who would like to pursue therapeutic intervention. Local therapy is appropriate for management of Old World CL as well as for treatment of New World CL caused by species unlikely to cause disseminated infection [<a href="#rid1">1</a>]. (See <a class="local">'Local therapy'</a> below.)</p><p>Systemic therapy is warranted for patients with complicated CL, for immunocompromised patients, for patients with spontaneously healing or recently healed lesions whose infection is known to be caused by a <em>Leishmania</em> species associated with increased risk for ML, and for patients with healing lesions whose species is unknown but whose infection was acquired within an area with <em>Leishmania</em> species associated with increased risk for ML [<a href="#rid1">1</a>]. Systemic therapy is also warranted for patients with less common syndromes including leishmaniasis recidivans, diffuse cutaneous leishmaniasis, and disseminated cutaneous leishmaniasis. (See <a class="local">'Overview of therapeutic approaches'</a> below and <a class="local">'Assessing risk for mucosal disease'</a> below and  <a class="medical medical_review" href="/z/d/html/5689.html" rel="external">"Cutaneous leishmaniasis: Clinical manifestations and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>The benefits of treatment include accelerated healing of skin lesions [<a href="#rid11">11,12</a>], reduced likelihood of recurrence (especially in the setting of subsequent immune compromise), diminished severity of skin scarring and attendant emotional concerns [<a href="#rid13">13,14</a>], and reduced risk for metastatic infection (which is important for individuals with immune compromise and/or for individuals with infection due to <em>Viannia</em> subgenus) [<a href="#rid15">15</a>]. In addition, in the setting of infection due to the anthroponotic species <em>L.L. tropica</em>, treatment may reduce the reservoir for transmission.</p><p>Consequences of no treatment or suboptimal treatment include scarring, superinfection, persistence of a chronic wound, and, for some <em>Leishmania</em> species, ML that may be destructive or disfiguring. In immunocompromised individuals, dissemination may occur.</p><p class="headingAnchor" id="H4101890031"><span class="h3">Assessing risk for mucosal disease</span><span class="headingEndMark"> — </span>In general, for Old World CL infection (eg, due to <em>L.L. tropica</em> or <em>L.L. major</em>) and for New World CL infection due to <em>L.L. mexicana</em>, the concern for later complications is relatively low and the lesions often heal in months. CL acquired in Central America north of Costa Rica, where <em>Viannia</em> subgenus is less frequently associated with ML, may not always require systemic therapy.</p><p>Systemic treatment for patients with CL acquired in the Americas south of Nicaragua is warranted, particularly in the setting of infection acquired in Brazil, Peru, or Bolivia. For these cases, a detailed nasal and oral examination must be performed to exclude mucosal involvement, which could modify treatment dosing and duration. Sampling of the skin lesion with culture and polymerase chain reaction (PCR) should be pursued as species identification may guide assessment for risk of later mucosal dissemination. </p><p>The use of systemic therapy to reduce risk of ML is based on observational evidence; lower rates of ML have been observed among patients who completed CL therapy than among those who received partial or no treatment [<a href="#rid15">15,16</a>]. However, subsequent development of ML has been observed among individuals treated with antimonials [<a href="#rid15">15,17</a>]. A re-evaluation of the limited evidence base provides a summary of the available published clinical experience [<a href="#rid2">2,18</a>]. These risks and benefits should be reviewed with patients, and a determination regarding treatment approach should be made based on individual circumstances. Patients should be counseled about the signs and symptoms of relapse or of ML and should be followed for at least three to five years.</p><p class="headingAnchor" id="H3505033"><span class="h2">Overview of therapeutic approaches</span><span class="headingEndMark"> — </span>Therapeutic agents and dosing for treatment of CL are summarized in the table  (<a class="graphic graphic_table graphicRef88693" href="/z/d/graphic/88693.html" rel="external">table 2</a>) [<a href="#rid2">2,3</a>].</p><p>The approach to treatment of CL is often influenced by the agents available [<a href="#rid2">2,3</a>]. In the United States, there is one therapeutic agent with approval for treatment of CL by the US Food and Drug Administration (FDA); oral <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a> is indicated for treatment of <em>L.V. braziliensis</em>, <em>L.V. guyanensis</em>, and <em>L.V. panamensis</em>. Other readily available treatment modalities include cryotherapy and thermotherapy. Relatively few dermatologists have experience treating CL via cryotherapy, and success correlates with experience. Thermotherapy devices may be less accessible; less skill with these devices is required for treatment success.</p><p>Available systemic agents in the United States include <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a>, azoles, amphotericin deoxycholate, and liposomal amphotericin. The efficacy of azoles is limited, and the duration of treatment is prolonged. Therefore, many use parenteral <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> given accessibility and short duration, even though evidence for efficacy is limited and the optimal dose remains uncertain. Use of amphotericin deoxycholate is limited by duration and toxicity but is quite effective.</p><p>In the United States, pentavalent antimonials and topical <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> are not available commercially but, meglumine antimoniate may be obtained via investigator-initiated investigational new drug (IND) protocol. Instructions on how to initiate the process to obtain these therapeutic agents can be found on the American Society of Tropical Medicine and Hygiene <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.astmh.org%2Fblog%2Fseptember-2022%2Finstructions-for-acquiring-glucantime-%28meglumine-a&amp;token=NALKBt6DwPABXaua0oyoBsrdErKTaG%2BmMqemqKym4edlRbMWn%2F7XHcXf7rBnTmwvZMgCw2Ye4aoC%2FzQm3dyayxiQA4Ma2hJ9U3Bwn8fO4%2Frhh%2B10avdkvdZ%2BDEJXZRRB&amp;TOPIC_ID=5686" target="_blank">website</a>. </p><p>Drug resistance varies by region; the same species may have variable response to a given drug depending on the geographic location. In addition, in some endemic areas, access to costly drugs and to species-level diagnosis for guiding treatment is limited. A species-directed review of treatment for CL in travelers provides evidence to support species identification to target therapy [<a href="#rid19">19</a>].</p><p>For New World CL, the Pan American Health Organization (PAHO) has issued updated GRADE guidelines, which heavily rely on the 2020 Cochrane review of interventions for American CL and ML [<a href="#rid2">2,20</a>]. The uptake of these recommendations remains to be seen given the significant changes in the guidelines, including marginalization of systemic pentavalent antimonial drugs except for ML, use of intralesional and topical therapy even in ML-causing species, elevation of <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a> in both adults and children, and no recommendation to identify species prior to therapy. The Infectious Diseases Society of America (IDSA) guidelines remain available to guide practice [<a href="#rid21">21</a>]. It is important to take into account that no therapy offers more than moderate efficacy and guidelines balance that fact with the cultural and societal values and restrictions in different parts of the world. Drug availability also affects the choice of treatment. For example, antimonial drugs are not easily available in the United States, topical <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> is relegated to poorly tested compounded formulations, and miltefosine is expensive, difficult to dose in heavier individuals, and not available in all dosing formulations in the United States. Furthermore, trials of miltefosine continue to show geographic differences in efficacy. PAHO, IDSA, and our recommendations value an individualized approach to care of localized CL. The appeal of better tolerated, nonparenteral agents with shorter courses has contributed to the emphasis of establishing guidelines for treatment of CL and ML, although the evidence base for steering the development of these guidelines remains thin. </p><p class="headingAnchor" id="H1791586"><span class="h3">Local therapy</span><span class="headingEndMark"> — </span>Local therapy is warranted for patients with uncomplicated CL (see <a class="local">'Whom to treat'</a> above). Local therapy is appropriate for management of Old World CL as well as for treatment of New World CL caused by species unlikely to cause disseminated infection  (<a class="graphic graphic_table graphicRef86988" href="/z/d/graphic/86988.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef110869" href="/z/d/graphic/110869.html" rel="external">figure 1</a>) [<a href="#rid1">1,22</a>]. In one series including 105 returned travelers to France with primarily <em>L.L. major</em> and <em>L.L. infantum</em>, 62 percent were managed without systemic therapy; cure rates were 92 percent for wound care only and 79 percent for local therapy [<a href="#rid23">23</a>]. There are few studies of intralesional therapy in New World CL acquired in the mucosal belt, but no ML cases were noted in follow-up [<a href="#rid24">24,25</a>].</p><p>Eschar(s) overlying ulcers should be debrided and secondary wound infection managed prior to administration of local therapy to maximize treatment effect [<a href="#rid1">1</a>]. Patients with subcutaneous nodules, regional adenopathy, and infection due to species associated with mucosal involvement should not be treated with local therapy alone, as it is less likely to control the infection.</p><p>The efficacy of local cryotherapy is greatest using a treatment approach combining cryotherapy immediately followed by intralesional pentavalent antimony (Sb<sup>V</sup>), which is widely used globally but is not available in the United States. Use of cryotherapy alone is appropriate for relatively small, nonulcerated lesions of recent onset. Thermotherapy alone can be used as an alternative to cryotherapy for management of patients with uncomplicated Old World or New World CL presenting with few and relatively small (≤25 mm) lesions. Thermotherapy and cryotherapy can also be used for follow-up management of residual lesions not fully healed after systemic treatment; in addition, both are acceptable for use during pregnancy and breastfeeding.</p><p>Topical <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> may be used for treatment of <strong>ulcerative</strong> lesions due to <em>L.L. major</em> or non-ML-associated Central American species; it is not generally used in conjunction with cryotherapy or thermotherapy. In Israel, use of topical paromomycin for treatment of <em>L.L. tropica</em> was effective in 70 percent of cases, so less than in <em>L.L. major,</em> but it could still be considered in individual patient situations [<a href="#rid26">26</a>]. In the United States, the availability of topical paromomycin is limited to a compounded ointment prepared from capsules; the efficacy of such preparations is uncertain, and they have not been studied in clinical trials. WR279,396 (a topical cream containing 15% paromomycin and 0.5% <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>) is no longer available.</p><p>Intralesional therapy with <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a> [<a href="#rid27">27</a>] or amphotericin [<a href="#rid28">28</a>] has been used successfully for treatment of both Old World CL and New World CL, in contrast to the more commonly used pentavalent antimonial drugs [<a href="#rid29">29</a>]. </p><p>Photodynamic therapy is a relatively new therapy; thus far, it appears promising, although data are limited [<a href="#rid30">30</a>].</p><p>Specific agents for local therapy are discussed further below. (See <a class="local">'Local therapy'</a> below.)</p><p class="headingAnchor" id="H2036958"><span class="h3">Oral systemic therapy</span><span class="headingEndMark"> — </span>Oral systemic agents include azoles and <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a>  (<a class="graphic graphic_table graphicRef88693" href="/z/d/graphic/88693.html" rel="external">table 2</a>).</p><p>In some cases, azoles can be used as systemic therapy, although the efficacy of azole therapy is limited and treatment failure is common. Clinical circumstances in which azoles have been used successfully include lymphocutaneous spread in the setting of non-ML-associated infection and cases in which the scope of cutaneous involvement is not amenable to local therapy. <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> and <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a> may be useful for treatment of <em>L.L. major</em>, <em>L.L. mexicana</em>, and possibly <em>L.V. panamensis</em>. Azoles may be used in combination with cryo- or thermotherapy for treatment of <em>L.L. major</em> with lymphocutaneous involvement.</p><p>Oral <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a> has reasonable efficacy against many New World CL species (compared with pentavalent antimonials). Data are limited regarding use of miltefosine for Old World CL, but it appears to have some efficacy. In the United States, miltefosine is available and FDA approved; this drug has become the treatment of choice for New World CL due to <em>Viannia </em>species.</p><p>Oral systemic therapy is discussed further below. (See <a class="local">'Oral systemic therapy'</a> below.)</p><p class="headingAnchor" id="H2036994"><span class="h3">Parenteral systemic therapy</span><span class="headingEndMark"> — </span>Parenteral agents for treatment of CL include pentavalent antimonials, amphotericin, and <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a>  (<a class="graphic graphic_table graphicRef88693" href="/z/d/graphic/88693.html" rel="external">table 2</a>). The optimal agent depends on individual clinical circumstances.</p><p>Both pentavalent antimonials and amphotericin derivatives have activity against Old World and New World CL. Antimonials historically are generally the mainstay of systemic parenteral therapy of CL, given observed success with antimonials and toxicity associated with use of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>. Small clinical series note liposomal amphotericin treatment efficacy of 80 to 85 percent [<a href="#rid31">31-33</a>], but a European series including 41 patients (treated with a median cumulative dose of 20 mg per kg) noted only 46 percent were healed at 90 days post treatment [<a href="#rid34">34</a>]; the efficacy of liposomal amphotericin was greatest in patients with <em>L. infantum</em> infection and least in patients with <em>Viannia</em> infection. <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">Pentamidine</a> is used largely for treatment of infection due to <em>L.V. guyanensis</em> but is generally a secondary therapy due to its adverse effect profile.</p><p>There are two parenteral pentavalent antimony agents: sodium stibogluconate and meglumine antimoniate. Historically, the antimonial drugs have good efficacy for reducing risk of progression to mucosal disease in New World CL. Parenteral Sb<sup>V</sup> has been the local standard of care for infection due to <em>Viannia</em> subgenus acquired in South America, especially in the mucosal belt, except for known foci of high antimonial resistance such as Madidi National Park, Bolivia, Manu National Park, and Puerto Maldonado, Peru. This may change with the PAHO guideline updates recommending use of <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a> in adults and children. Treatment with systemic antimonials is also appropriate in the setting of complicated Old World CL that has not responded to local therapy. In the United States, antimonial drugs are available only via an investigator-initiated IND protocol; instructions on how to obtain these drugs are available through the American Society of Tropical Medicine and Hygiene <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.astmh.org%2Fblog%2Fseptember-2022%2Finstructions-for-acquiring-glucantime-%28meglumine-a&amp;token=NALKBt6DwPABXaua0oyoBsrdErKTaG%2BmMqemqKym4edlRbMWn%2F7XHcXf7rBnTmwvZMgCw2Ye4aoC%2FzQm3dyayxiQA4Ma2hJ9U3Bwn8fO4%2Frhh%2B10avdkvdZ%2BDEJXZRRB&amp;TOPIC_ID=5686" target="_blank">website</a>.</p><p><a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">Amphotericin B deoxycholate</a> has the greatest efficacy against CL (based on case series, not controlled trials), but its use is somewhat limited by toxicity. Liposomal amphotericin circumvents some of the toxicity and may permit a shorter duration of treatment; further studies are needed to fully evaluate its use for treatment of CL, including the appropriate dose and duration. Liposomal amphotericin has become a commonly used agent for treatment of CL in regions where available.</p><p>Parenteral systemic therapy is discussed further below. (See <a class="local">'Parenteral systemic therapy'</a> below.)</p><p class="headingAnchor" id="H2037030"><span class="h2">Specific therapeutic agents</span></p><p class="headingAnchor" id="H5913957"><span class="h3">Local therapy</span><span class="headingEndMark"> — </span>An overview of local therapy is discussed above. (See <a class="local">'Local therapy'</a> above.)</p><p class="headingAnchor" id="H1791641"><span class="h4">Cryotherapy</span><span class="headingEndMark"> — </span>Use of cryotherapy is often restricted to Old World disease since there is no risk for metastases and less lymphocutaneous involvement with these species. Cryotherapy may be used for infection of recent onset (less than three months' duration), disease with relatively few and relatively small lesions (&lt;3 cm), nodular lesions, and for individuals who cannot use systemic treatment. The efficacy of cryotherapy in clinical trials ranges from 53 to 100 percent; the efficacy is increased when cryotherapy is used in combination with intralesional pentavalent antimonials [<a href="#rid35">35-38</a>].</p><p>In general, cryotherapy with liquid nitrogen consists of a freeze, thaw, freeze cycle, which causes intracellular ice to form, destroying cells, and leads to localized ischemic necrosis. It is important to treat into normal-appearing tissue around the lesions. One series including 293 patients in Saudi Arabia described a method of cryotherapy involving placement of a cotton-tipped applicator with liquid nitrogen directly on the lesion, freezing 15 to 20 seconds (until 1 to 2 mm of circumferential normal appearing skin appears frozen), thawing 20 to 60 seconds, and freezing again [<a href="#rid39">39</a>]. This sequence was repeated at three-week intervals up to three times or until healing occurred.</p><p>Adverse effects of cryotherapy include erythema, edema of the perilesional area, occasional blistering, permanent hypopigmentation (in dark-skinned individuals), hyperpigmentation, and scar.</p><p class="headingAnchor" id="H3505048"><span class="h4">Thermotherapy</span><span class="headingEndMark"> — </span>Dermatotrophic leishmaniasis species, such as <em>L.L. mexicana</em>, <em>L.L. major</em>, and <em>L.L. tropica</em>, are thermosensitive; their ability to replicate is limited at higher temperatures [<a href="#rid40">40</a>]. Heat treatment of cutaneous leishmaniasis can be delivered by several methods; a radiofrequency instrument, ThermoMed, has received FDA approval for this purpose. Studies evaluating efficacy of radiofrequency thermotherapy for treatment of CL due to <em>L.L. major</em>, <em>L.L. tropica</em>, <em>L.V. panamensis</em>, and <em>L.V. braziliensis </em>have observed clinical cure rates of 54 to 73 percent at two to three months following treatment [<a href="#rid41">41-44</a>].</p><p>The radiofrequency instrument is portable, battery operated, and delivers superficial heat to 50°C via a set of prongs placed directly on the lesion. The treatment is painful, and local anesthesia is required. Prongs are touched to the lesion for 30-second heat intervals in a grid pattern over the lesion as well as a 1 to 2 mm border of normal-appearing skin. Most trials have used a single treatment session, although up to three treatments have been reported. The probes are not disposable and require sterilization between patients.</p><p>Thermotherapy can cause second-degree burns; up to a week of topical antibiotic therapy and a wound dressing are warranted. Local pain at the site lasts approximately 24 hours and is comparable to sunburn. Other adverse effects include blistering, oozing, and erythema. In general, the cosmetic outcome is relatively good; little permanent hypopigmentation or significant keloid formation has been observed following thermotherapy, in contrast with cryotherapy.</p><p>Thermotherapy alone should not be used for lesions with potential for lymphocutaneous or mucosal spread. It should not be used directly over superficial nerves, cartilage, eyelids, nose, or lips.</p><p class="headingAnchor" id="H3505062"><span class="h4">Intralesional pentavalent antimony</span><span class="headingEndMark"> — </span>Intralesional injection of sodium stibogluconate or meglumine antimoniate is a reasonable approach for treatment of localized CL lesions ≤1 cm  (<a class="graphic graphic_table graphicRef88693" href="/z/d/graphic/88693.html" rel="external">table 2</a>) [<a href="#rid20">20</a>]. The treatment is most effective for management of lesions due to CL species not associated with mucosal or lymphocutaneous involvement. The optimal dosing regimen is uncertain; few randomized controlled trials have been performed [<a href="#rid35">35,45-47</a>]. We favor injection of 0.2 to 5 mL per session every three to seven days (up to three weeks between treatments is also acceptable) in combination with cryotherapy [<a href="#rid5">5,48</a>]. A total of five to eight treatment sessions (or until clinical healing is observed) is appropriate. The efficacy depends on the technical skill of the treating provider and close follow-up for continued treatments.</p><p>Treatment consists of injection of up to five sites per lesion with a 25- to 27-gauge needle, for an estimated dose of 0.1 mL per cm<sup>2</sup>. The needle should be advanced while injecting under pressure into the upper and mid-dermis of the lesion and border circumferentially, until the lesion is blanched  (<a class="graphic graphic_picture graphicRef100574" href="/z/d/graphic/100574.html" rel="external">picture 1</a>). The procedure is painful; in adults, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>/<a class="drug drug_general" data-topicid="10228" href="/z/d/drug information/10228.html" rel="external">prilocaine</a> cream may be used, while children may need to be anesthetized. Treatment may be repeated up to five to eight times or until healed. Adverse effects include local allergic reaction, pain, edema, pruritus, and transient erythema. Intralesional antimony should be avoided on fingers, nose, ear, eyelid, and near lip.</p><p>This route of antimonial administration is not available in the United States except by investigator-IND protocol (and can be accessed through the American Society of Tropical Medicine and Hygiene <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.astmh.org%2Fblog%2Fseptember-2022%2Finstructions-for-acquiring-glucantime-%28meglumine-a&amp;token=NALKBt6DwPABXaua0oyoBsrdErKTaG%2BmMqemqKym4edlRbMWn%2F7XHcXf7rBnTmwvZMgCw2Ye4aoC%2FzQm3dyayxiQA4Ma2hJ9U3Bwn8fO4%2Frhh%2B10avdkvdZ%2BDEJXZRRB&amp;TOPIC_ID=5686" target="_blank">website</a>).</p><p class="headingAnchor" id="H3505069"><span class="h4">Topical paromomycin</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> (also called aminosidine) is an aminoglycoside in the form of an ointment or cream  (<a class="graphic graphic_table graphicRef88693" href="/z/d/graphic/88693.html" rel="external">table 2</a>). Topical paromomycin is most useful for treatment of ulcerative infection due to <em>L.L. major</em> with small (≤5 cm), relatively few lesions in the absence of lymphocutaneous involvement. A meta-analysis of 14 trials with 1221 patients treated with topical paromomycin noted that paromomycin ointment had therapeutic activity against both Old World and New World CL (relative risk [RR] for clinical cure versus placebo 2.58 versus 1.01) [<a href="#rid49">49</a>]. For treatment of Old World CL, the efficacy of topical paromomycin is comparable with that of intralesional antimonials. For treatment of New World CL, topical paromomycin is inferior to parenteral antimonial therapy (RR 0.67; 95% CI 0.54-0.82) [<a href="#rid49">49</a>]. However, a Cochrane systematic review concluded that there was no difference in cure rates for paromomycin ointment compared with vehicle for treatment of Old World CL [<a href="#rid3">3</a>]. </p><p>Formulations of topical <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> differ in efficacy and include preparations with methylbenzethonium or <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>. An ointment consisting of 15% paromomycin and 12% methylbenzethonium (Leishcutan) was effective among 87 percent of 67 patients with CL due to <em>L.L. major</em> [<a href="#rid50">50</a>]. Adverse effects included localized pain, skin irritation, and edema. This preparation is not so effective for treatment of CL due to <em>L.L. tropica </em>[<a href="#rid26">26</a>]. An ointment of 15%/10% urea in soft white paraffin has been studied in Iran and Tunisia; efficacy was insufficient [<a href="#rid51">51,52</a>].</p><p>WR279,396 is a topical cream consisting of 15% <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> and 0.5% <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> in a hydrophilic base [<a href="#rid49">49,53-55</a>]. The drug is administered once daily for 20 days. It has been studied in Panama, Colombia, and Tunisia (<em>L.L. major</em> and <em>L.V. panamensis </em>primarily) and shown to have cure rates of 71 to 99 percent [<a href="#rid49">49,53-55</a>]. Following treatment, the scar is usually not retracted. Side effects include erythema and mild pain. The formulation WR279,396 is no longer available. </p><p>Topical <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> can be compounded in the United States using oral capsules. A home brewed topical ointment can be compounded using 15% paromomycin and 12% methylbenzethonium in soft white paraffin; however, the performance characteristics for this formulation are not known. In addition, WR279,396 cream can be approximated by compounding Unibase ointment with 15% (free base) paromomycin sulfate, 0.5% <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> sulfate, 6.75% urea, and purified water (42.2 percent) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3505076"><span class="h4">Photodynamic therapy</span><span class="headingEndMark"> — </span>Photodynamic therapy (PDT) destroys tissue by generating reactive oxygen species, which interfere with normal cell function. Treatment consists of administration of a photosensitizing compound (such as with 5-aminolaevulinic acid) that selectively accumulates in the target tissue, followed by irradiation [<a href="#rid30">30</a>].</p><p>PDT is a relatively new therapy; thus far, it appears promising, although data are limited. In one trial including 60 patients with Old World CL treated with PDT, <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a>, or placebo, complete cure after two months was observed more frequently among patients treated with PDT than the other groups (93, 41, and 13 percent, respectively) [<a href="#rid56">56</a>]. The cosmetic results of PDT were good, with superficial or minimal scar.</p><p class="headingAnchor" id="H5913965"><span class="h3">Oral systemic therapy</span><span class="headingEndMark"> — </span>An overview of oral systemic therapy is discussed above. (See <a class="local">'Oral systemic therapy'</a> above.)</p><p class="headingAnchor" id="H3505614"><span class="h4">Azoles</span><span class="headingEndMark"> — </span>Azole drugs alter biosynthesis of ergosterol, thereby modifying the components of the <em>Leishmania</em> parasite membrane  (<a class="graphic graphic_table graphicRef88693" href="/z/d/graphic/88693.html" rel="external">table 2</a>) [<a href="#rid57">57</a>]. The use of azoles is limited to specific circumstances depending on geography and the infecting species. Parasite speciation is important to tailor the approach to azole therapy. <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">Ketoconazole</a> has reasonable clinical efficacy for treatment of CL due to <em>L.L. mexicana</em>, <em>L.V. panamensis</em>, and <em>L.L. major </em>but has significant risks of hepatotoxicity or QT prolongation<em> </em>[<a href="#rid12">12,58,59</a>]. <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> is effective against <em>L.L. major</em> in Saudi Arabia, although <em>L.L. major</em> in North Africa and Iraq appears to be less responsive to fluconazole; higher doses may improve efficacy.</p><p><a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">Ketoconazole</a> was more effective than sodium stibogluconate for treatment of <em>L.L. mexicana</em> infection (89 versus 57 percent, respectively) in one study including 120 Guatemalan patients with CL [<a href="#rid12">12</a>]. However, for treatment of <em>L. braziliensis</em> infection, ketoconazole was less effective than sodium stibogluconate (30 versus 96 percent, respectively) [<a href="#rid12">12</a>]. In a study including 96 Iranian patients with CL (likely <em>L.L. major</em>), clinical cure rates were higher with ketoconazole than with intralesional meglumine antimoniate (89 versus 72 percent, respectively) [<a href="#rid58">58</a>].</p><p><a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> is effective against <em>L.L. major</em> in Saudi Arabia. In one study including 209 patients with <em>L.L. major</em> infection in Saudi Arabia, healing was observed more frequently among patients who received fluconazole (200 mg daily for six weeks) than placebo (59 versus 22 percent) [<a href="#rid60">60</a>]. However, <em>L.L. major</em> in North Africa and Iraq appears to be less responsive to fluconazole [<a href="#rid61">61</a>]. In some circumstances, fluconazole may be more effective at higher doses than lower doses. Among 120 patients with <em>L.L. major</em> in Iran, the relative risk of healing was higher among patients on fluconazole 400 mg daily than among patients on fluconazole 200 mg daily (RR 4.57; 95% CI 1.99-10.46) [<a href="#rid62">62</a>].</p><p><a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> is not effective for treatment of CL due to <em>L.V. braziliensis</em> or <em>L.V. guyanensis </em>[<a href="#rid63">63,64</a>]. In one randomized trial including 53 patients infected with <em>L.V. braziliensis</em> and treated with fluconazole (6.5 to 8 mg/kg orally per day) or Sb<sup>V</sup> (20 mg/kg parenterally per day), healing at two months among patients treated with fluconazole was observed in only 22 percent of cases [<a href="#rid63">63</a>]. </p><p><a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">Posaconazole</a> was successful in a case report of a traveler with a single nodular lesion due to <em>L.L. infantum</em> [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H3505622"><span class="h4">Miltefosine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">Miltefosine</a> is an oral alkylphosphocholine drug known as hexadecylphosphocholine; it has activity against cutaneous, mucosal, and visceral leishmaniasis (VL)  (<a class="graphic graphic_table graphicRef88693" href="/z/d/graphic/88693.html" rel="external">table 2</a>) [<a href="#rid66">66</a>]. Miltefosine interacts with parasite membrane constituents and can affect lipid-dependent cell signaling pathways by inhibiting Akt (also known as protein kinase B) [<a href="#rid67">67</a>]. Miltefosine also interferes with glycosylphosphatidyl inositol anchors [<a href="#rid67">67</a>]. In 2014, the FDA approved miltefosine for the treatment of ML, VL due to <em>L.L. donovani</em>, and CL due to <em>L.V. braziliensis</em>, <em>L.V. guyanensis</em>, and <em>L.V. panamensis </em>for individuals &gt;12 years old. </p><p>Most data available for use of <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a> address treatment of New World CL. The efficacy of miltefosine for treatment of New World CL varies both by species and by geography within a particular species [<a href="#rid68">68,69</a>]. Miltefosine appears to have clinical utility for treatment of <em>L.V. panamensis</em>, <em>L.V. guyanensis</em>, <em>L.L. mexicana</em>, and <em>L.V. braziliensis </em>infection in Colombia and Brazil [<a href="#rid2">2,70-75</a>]. Miltefosine shows efficacy in the treatment of <em>L.V. braziliensis</em> in Bolivia (70 to 88 percent) and Brazil (75 percent) but not in Guatemala (45 percent) [<a href="#rid70">70,76,77</a>].</p><p>Data on use of <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a> for treatment of Old World CL are limited [<a href="#rid68">68,69,78-80</a>]. Among 63 Iranian patients with <em>L.L. major</em> infection, the efficacy of miltefosine and intramuscular meglumine antimoniate were comparable (81 percent at three months after treatment) [<a href="#rid78">78</a>]. In an observational study of 95 Ethiopian patients with <em>L.L.</em> <em>aethiopica</em>, miltefosine was associated with 48.7 percent clinical cure at day 180 and 32 percent relapse rate [<a href="#rid81">81</a>].</p><p>Oral absorption of <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a> is relatively slow, and the elimination half-life is 30.9 days [<a href="#rid82">82</a>]. In one study of serial skin biopsies performed during miltefosine treatment, the rate of parasite load decline for <em>L.L. major</em> and <em>L.L. infantum </em>was about one log/week, and high skin levels of miltefosine were demonstrated at the end of treatment [<a href="#rid83">83</a>].</p><p>Gastrointestinal effects of <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a> include anorexia, nausea, vomiting, or diarrhea; administration of miltefosine with fatty foods may reduce these symptoms, but the effect on bioavailability is not known. Elevated serum transaminases and creatinine concentration may also occur [<a href="#rid84">84</a>]. Ocular toxicity has been described during treatment of post-kala-azar dermal leishmaniasis [<a href="#rid85">85,86</a>].The use of miltefosine is contraindicated in pregnant women [<a href="#rid87">87</a>]. Women of childbearing potential should use contraception during treatment and for five months following treatment with miltefosine [<a href="#rid88">88</a>].</p><p>Oral <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a> has reasonable efficacy against many New World CL species (compared with pentavalent antimonials); this advantage must be weighed against adverse events, cost, and availability. The package insert cites an upper dosage limit of 150 mg per day because of poor gastrointestinal tolerability. Limited data are available for individuals &gt;75 kg, but a lower clinical response rate has been observed in individuals receiving less than 2.5 mg/kg per day.</p><p class="headingAnchor" id="H5913973"><span class="h3">Parenteral systemic therapy</span><span class="headingEndMark"> — </span>An overview of parenteral systemic therapy is discussed above. (See <a class="local">'Parenteral systemic therapy'</a> above.)</p><p class="headingAnchor" id="H3505637"><span class="h4">Parenteral pentavalent antimony</span><span class="headingEndMark"> — </span>There are two parenteral pentavalent antimony agents: sodium stibogluconate (sodium antimony gluconate, Pentostam) and meglumine antimoniate (N-methyl glucamine antimoniate, Glucantime)  (<a class="graphic graphic_table graphicRef88693" href="/z/d/graphic/88693.html" rel="external">table 2</a>) [<a href="#rid89">89,90</a>]. The pentavalent antimonial drugs affect adenosine triphosphate (ATP) synthesis, and it has been suggested that they inhibit glycolysis, affecting fatty acid oxidation [<a href="#rid91">91</a>]. Sodium stibogluconate has been identified to have effects on cell signaling, leading to increased interferon-gamma production in <em>Leishmania</em>-infected macrophages [<a href="#rid92">92</a>].</p><p>The parenteral pentavalent antimony agents generally can be considered clinically equivalent, though it is important to note that they contain different antimony concentrations; sodium stibogluconate contains 100 mg/mL Sb<sup>V</sup> and meglumine antimoniate contains 81 mg/mL Sb<sup>V</sup> [<a href="#rid93">93-96</a>]. For decades, these drugs have been a standard therapy for CL; they are especially important for management of infection with potential for mucosal progression [<a href="#rid20">20</a>]. This is particularly important in the setting of clinical unresponsiveness to therapy, which requires higher doses and longer duration of therapy and can result in increased toxicity.</p><p>More data are available regarding use of parenteral antimonials for treatment of New World CL than for treatment of Old World CL [<a href="#rid12">12,59,97</a>]. One meta-analysis including 1150 patients with New World CL noted a comparable cure rate with pentavalent antimonials and <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a> (76 percent) [<a href="#rid98">98</a>]. No differences in efficacy between species were observed (although most infections were due to <em>L.V. braziliensis</em>), but there were differences in efficacy between regions, with greater efficacy in Colombia than Brazil (91 versus 71 percent, respectively) [<a href="#rid98">98</a>]. It has been observed that early treatment of New World CL (eg, treatment of patients with only superficial ulceration and/or less than 30 days of illness) with parenteral antimonials does not prevent ulceration and is associated with high rates of treatment failure [<a href="#rid11">11</a>].</p><p>The efficacy of parenteral antimonials for treatment of Old World CL is 60 to 80 percent [<a href="#rid99">99</a>]. Among 64 Iranian patients with likely <em>L.L. major</em>, combination therapy with meglumine antimoniate plus <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> was more likely to be associated with a complete response rate than meglumine antimoniate plus placebo (81 versus 52 percent) [<a href="#rid100">100</a>].</p><p>Pentavalent antimonial drugs are administered by intramuscular or intravenous routes for systemic therapy. Dosing for sodium stibogluconate or meglumine antimoniate consists of 20 mg Sb<sup>V</sup>/kg/day (there is no upper limit in contrast with the information in the package insert) in a single daily dose infused over 15 to 30 minutes for 20 days. Expert consultation regarding dose should be pursued for management of patients with obesity. Pentavalent antimonials accumulate in renal insufficiency. The rate of antimony clearance is higher in children than adults, which may explain why lower antimonial response rates have been observed among children compared with adults [<a href="#rid101">101,102</a>].</p><p>Adverse effects include myalgias and arthralgias (these generally occur after seven days of therapy), early elevation of pancreatic enzymes (though clinical pancreatitis occurs less frequently), rash, nausea, abdominal pain, fatigue, headaches, elevated transaminases, mild leukopenia, and nonspecific ST wave changes on electrocardiography [<a href="#rid103">103-107</a>]. Less common findings include anemia, thrombocytopenia, reactivation of herpes simplex and varicella-zoster viruses, and QT prolongation [<a href="#rid108">108</a>]. Rare but serious side effects include angioedema and severe pancreatitis [<a href="#rid109">109</a>]. In general, most effects are reversible, and management is symptomatic; nonsteroidal drugs may be administered for musculoskeletal pain [<a href="#rid107">107</a>]. In the setting of elevated pancreatic enzymes, the drug should be held for a few days until levels normalize. In general, weekly electrocardiogram and blood counts should be monitored during therapy, in addition to serum concentrations of creatinine, amylase, lipase, and transaminases. The pentavalent antimonial drugs are contraindicated during pregnancy and breastfeeding [<a href="#rid110">110,111</a>].</p><p>The therapeutic response to treatment of leishmaniasis is influenced by multiple factors, including pharmacologic factors, the host immune status, and the variable biology of <em>Leishmania</em> species. These factors confound correlation of clinical outcomes with drug susceptibility and the possibility of resistance [<a href="#rid112">112</a>]. Diminished response to pentavalent antimony has been observed among <em>L.V. braziliensis</em>, <em>L.L. tropica</em>, and <em>L.L. aethiopica</em>, with some geographic variability. Failure of pentavalent antimonial drugs has been associated with increased duration of skin lesions, multiple lesions, age of patient, large lesions, parasite species, and concomitant helminth infection [<a href="#rid113">113,114</a>].</p><p>In the United States, sodium stibogluconate is not available and meglumine antimoniate is only available through an investigator-initiated IND protocol; instructions can be accessed through the American Society of Tropical Medicine and Hygiene <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.astmh.org%2Fblog%2Fseptember-2022%2Finstructions-for-acquiring-glucantime-%28meglumine-a&amp;token=NALKBt6DwPABXaua0oyoBsrdErKTaG%2BmMqemqKym4edlRbMWn%2F7XHcXf7rBnTmwvZMgCw2Ye4aoC%2FzQm3dyayxiQA4Ma2hJ9U3Bwn8fO4%2Frhh%2B10avdkvdZ%2BDEJXZRRB&amp;TOPIC_ID=5686" target="_blank">website</a>. Since alternative options such as oral <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a> and <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> have less serious adverse events than antimonial drugs, these options have become preferred in practice. The use of intralesional pentavalent antimonial drugs is still recommended, however. </p><p class="headingAnchor" id="H18323512"><span class="h4">Amphotericin B</span><span class="headingEndMark"> — </span>There are two formulations of amphotericin B used in the treatment of CL: <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> and <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (Ambisome)  (<a class="graphic graphic_table graphicRef88693" href="/z/d/graphic/88693.html" rel="external">table 2</a>). Amphotericin B is a polyene antibiotic; the drug binds to ergosterol precursors in preference to host cholesterol, leading to increased parasite membrane permeability resulting in cell death [<a href="#rid115">115</a>].</p><p>Use of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> is limited by long duration of intravenous therapy (hours of infusion daily for 20 to 30 days) and potential irreversible nephrotoxicity. <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">Liposomal amphotericin B</a> consists of amphotericin incorporated into liposomes that targets to the drug to macrophages, where the parasite is concentrated; the preparation is also associated with lower rates of nephrotoxicity than amphotericin B deoxycholate. Case series data suggest that patients with ML may benefit from treatment with liposomal amphotericin [<a href="#rid116">116-118</a>]; this data might be extrapolated to suggest that CL patients treated with liposomal amphotericin may have decreased risk for future ML, although further study is needed. Other lipid amphotericin agents have not been studied sufficiently for treatment of CL, but reports suggest they may not have equivalent efficacy [<a href="#rid119">119,120</a>]. (See <a class="local">'Mucosal leishmaniasis'</a> below.)</p><p>Adverse effects of amphotericin B include nephrotoxicity, hypokalemia, anemia, peripheral vein phlebitis, and fever with rigors related to infusion. The risk of nephrotoxicity associated with amphotericin B may be increased among patients previously treated with pentavalent antimonials; <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> loading may reduce nephrotoxicity [<a href="#rid121">121</a>]. In addition, baseline QT prolongation may be potentiated in the setting of hypokalemia induced by amphotericin B, which can lead to cardiac arrhythmia; a wash-out period of at least two weeks between the two treatments (antimonials and amphotericin) is warranted [<a href="#rid122">122,123</a>]. Additional side effects associated with liposomal amphotericin treatment in CL include infusion-related chest or flank pain, dyspnea, urticaria, and flushing [<a href="#rid124">124</a>].</p><p>Dosing of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> for treatment of cutaneous leishmaniasis is 0.5 to 1 mg/kg/day or every other day for a cumulative dose of 15 to 30 mg/kg; the World Health Organization recommends 0.7 mg/kg/day for 25 to 30 days [<a href="#rid5">5</a>]. Dosing of liposomal amphotericin is uncertain; it is unclear whether the dosing regimen for visceral leishmaniasis is optimal for treatment of CL [<a href="#rid119">119,120,125</a>]. Some efficacy has been observed with administration of relatively short course of liposomal amphotericin (3 mg/kg for five consecutive days and a sixth dose on day 10); a European case series showed an initial healing response at three months of only 46 percent [<a href="#rid32">32,34</a>].</p><p>Data on the efficacy of amphotericin relative to antimonials are limited [<a href="#rid32">32,126,127</a>]. In a controlled trial of low-dose liposomal amphotericin (1.5 mg Sb<sup>V</sup>/kg/day for five doses) versus meglumine antimoniate (20 mg/kg/day intravenously for 20 doses) among 35 Brazilian patients with cutaneous leishmaniasis, cure rates were 50 and 100 percent, respectively [<a href="#rid127">127</a>]. In a case series including patients with <em>L.V. braziliensis </em>CL, 34 patients were treated with liposomal amphotericin (3 mg/kg/day for six doses) and 34 patients treated with sodium stibogluconate (20 mg/kg/day for three weeks). Healing was observed in 97 and 71 percent of patients, respectively, and liposomal amphotericin was better tolerated than sodium stibogluconate [<a href="#rid32">32</a>]. In smaller series including patients with Old World CL, 84 percent responded to liposomal amphotericin (3 mg/kg/day for six or more doses) [<a href="#rid124">124,128</a>].</p><p class="headingAnchor" id="H4278661"><span class="h4">Pentamidine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">Pentamidine</a> isoethionate is an alternative parenteral treatment for cutaneous leishmaniasis  (<a class="graphic graphic_table graphicRef88693" href="/z/d/graphic/88693.html" rel="external">table 2</a>). It is an aromatic diamidine compound; its mechanism of action is thought to be through interference with DNA synthesis, modifying the <em>Leishmania </em>kinetoplast morphology and causing fragmentation of mitochondrial membranes [<a href="#rid129">129</a>]. Its many adverse effects have relegated it to a secondary therapy, largely reserved for <em>L.V. guyanensis </em>infection acquired in the Guyanas [<a href="#rid20">20</a>].</p><p>Data are limited regarding use of <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a> for treatment of Old World CL. In one small series of 11 European patients with infections due to <em>L.L. tropica</em>, <em>L.L. major</em>, or <em>L.L. infantum</em>, treatment with pentamidine (4 mg/kg intramuscularly every other day for three doses) resulted in 73 percent clinical response [<a href="#rid130">130</a>].</p><p>There are more data regarding use of <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a> for treatment of New World CL than Old World CL [<a href="#rid131">131</a>]. Pentamidine appears to have greatest efficacy against <em>L.V. guyanensis</em> infection acquired in Guyana, French Guiana, and Suriname; among several studies with different regimens and endpoints (including more than 1000 patients cumulatively), efficacy ranged 73 to 95 percent [<a href="#rid132">132-137</a>]. In studies in Colombia, higher total dose (either more doses or higher dose) was linked to efficacy of 96 percent [<a href="#rid138">138,139</a>]. The appropriate dose for pentamidine isethionate is 7 mg/kg weekly for three doses [<a href="#rid140">140</a>]; the intravenous route of administration is preferred for efficacy [<a href="#rid141">141</a>].</p><p><a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">Pentamidine</a> has a significant adverse event profile, including drug-induced pancreatitis leading to insulin-dependent diabetes, dysglycemia (especially reversible hypoglycemia), hypotension, QT prolongation, hyperkalemia, cytopenias, nephrotoxicity, and elevated liver-associated enzymes. Other adverse events reported include pain at the injection site, sterile abscesses, dysgeusia, myalgias (increased creatine phosphokinase levels), nausea, and headache.</p><p class="headingAnchor" id="H4273660"><span class="h2">Clinical follow-up</span><span class="headingEndMark"> — </span>Patients should be followed for 6 to 12 months to evaluate for relapse; patients at risk for ML should be followed for at least two years [<a href="#rid1">1</a>]. Treatment response is generally assessed by physical appearance. A careful nasal and oropharyngeal examination should also be performed. Lesion sampling for parasitologic assessment is not necessary if the lesion appears to be healing clinically.</p><p>Healing of CL is slow and continues after treatment has been completed; lesions are rarely completely healed at the end of treatment. The first sign of healing is usually flattening of the skin lesion. A paradoxical increase in the local inflammatory response may be seen in the first two to three weeks of treatment and can be difficult to differentiate from therapeutic failure. By four to six weeks following treatment, the lesion size should be decreased by more than 50 percent, with improvement in edema and inflammation. Ulcers should be reepithelializing, and no new lesions should be appearing [<a href="#rid142">142</a>]. Ulcers are generally reepithelialized or "clinically cured" approximately three months following treatment [<a href="#rid2">2,3</a>].</p><p>Relatively little improvement or worsening while on therapy (usually seen at the border of a healed lesion) suggests an inadequate response and should prompt additional therapy (but not necessarily a different agent or approach). Additional therapy is also warranted if there is incomplete healing by three months after completion of treatment. For management of patients who relapse or do not respond to treatment, consultation with a leishmaniasis expert is warranted.</p><p>Patients with symptoms such as chronic nasal stuffiness, epistaxis, or hoarseness or findings such as septal perforation should prompt evaluation for ML, including referral to a specialist for endoscopic otorhinolaryngologic examination if relevant.</p><p class="headingAnchor" id="H1449746305"><span class="h2">Wound care</span><span class="headingEndMark"> — </span>Ulcerative CL is a chronic wound [<a href="#rid143">143</a>]. Secondary bacterial infection inhibits healing, permits further enlargement of the lesion, and can cause surrounding cellulitis. Lesions should be gently cleaned daily with mild soap and water. If purulence is observed, the overlying eschar should be debrided to a clean base. A thin layer of a petroleum-based ointment should be applied after bathing. Occlusive dressings are not needed but can be used if there is associated wound drainage [<a href="#rid144">144</a>]. Trauma may interrupt healing or cause lesions to develop at sites of trauma remote to initial lesion. Cosmetic surgery and/or skin grafts should be postponed until at least a year after successful healing [<a href="#rid145">145</a>].</p><p class="headingAnchor" id="H2037869"><span class="h1">MUCOSAL LEISHMANIASIS</span><span class="headingEndMark"> — </span>Mucosal leishmaniasis (ML) occurs most frequently in the New World and is characterized by mucosal destruction. (See  <a class="medical medical_review" href="/z/d/html/5689.html" rel="external">"Cutaneous leishmaniasis: Clinical manifestations and diagnosis", section on 'Mucosal leishmaniasis'</a>.)</p><p>Cure is difficult unless ML is identified while mild; the goals of treatment include preventing morbidity (eg, disfigurement) and mortality (eg, from aspiration pneumonia or respiratory obstruction) [<a href="#rid1">1</a>]. There are few randomized controlled trials to guide treatment of ML; a long duration of therapy is required, and close follow-up for relapse is warranted.</p><p>Prior to initiation of therapy, a complete examination of the naso-oropharyngeal and laryngeal mucosa should be conducted by an otolaryngologist to assess the extent and clinical severity of mucosal disease. In the setting of laryngeal/pharyngeal disease and increased risk for respiratory obstruction (as indicated by symptoms, otolaryngologic and/or radiographic examination), inpatient monitoring and prophylactic corticosteroid therapy are warranted at the time of treatment initiation; these may reduce the risk of cyanosis, dyspnea, and need for emergent tracheostomy [<a href="#rid1">1</a>].</p><p>There are few randomized controlled trials to guide treatment of ML; a long duration of therapy is required, and close follow-up for relapse is warranted [<a href="#rid146">146</a>]. Therapeutic options for treatment of ML include parenteral pentavalent antimony drugs, amphotericin B including liposomal amphotericin, and <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a> (used for treatment of Bolivian ML)  (<a class="graphic graphic_table graphicRef88694" href="/z/d/graphic/88694.html" rel="external">table 3</a>) [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In general, initial management of ML should consist of parenteral therapy. The recommended treatment option by the PAHO is pentavalent antimony in combination with <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> for synergistic activity [<a href="#rid2">2,20,74,147</a>]. However, the efficacy of pentavalent antimonials in ML is variable depending on geography, severity of presenting infection, parasite species, and duration of treatment [<a href="#rid148">148-150</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> is somewhat limited by toxicity, though case series have demonstrated that it is associated with a better response rate and lower relapse rate than pentavalent antimony. The toxicity of <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> is less than amphotericin B deoxycholate and is comparable with that of antimonials, though data are limited regarding the optimal dose and duration of therapy; its use is also limited by cost.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">Miltefosine</a> has demonstrated good efficacy in the treatment of Bolivian ML and is US Food and Drug Administration approved for use in ML due to <em>L.V. braziliensis</em>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">Pentamidine</a> is rarely used to treat ML given its adverse effect profile during a long course of treatment [<a href="#rid151">151</a>].</p><p></p><p>A systematic review including 68 studies and 271 patients with ML noted an overall treatment efficacy of 67 percent [<a href="#rid152">152</a>]. Pentavalent antimonial drugs were the most commonly used agents; the efficacy among Brazilian, Peruvian, and Panamanian patients was 88, 51, and 51 percent, respectively. In a retrospective review of 140 Brazilian patients, meglumine antimoniate was administered to approximately half of patients with a cure rate of 91 percent and a recurrence rate of 22 percent [<a href="#rid116">116</a>]. Primary resistance to antimonials was observed in 14 percent of cases; most resistance was related to use of doses &lt;10 mg/kg and shorter duration of therapy.</p><p>Among 23 Brazilian patients with <em>L.V. braziliensis</em>, patients treated with sodium stibogluconate (20 mg/kg/day for 30 doses) plus <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> (400 mg orally three times daily for 30 days) healed faster than those treated with sodium stibogluconate alone (100 versus 40 percent healing at six months following treatment) [<a href="#rid147">147</a>]. The benefit of pentoxifylline may be related to its ability to downregulate tumor necrosis factor (TNF)-alpha production, which is expressed in high levels in ML lesions.</p><p><a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">Amphotericin B deoxycholate</a> has therapeutic activity for ML. Among Brazilian and Bolivian patients with mucosal disease, 90 to 96 percent who completed therapy (1 mg/kg until healing, in combination with <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>) were clinically cured [<a href="#rid153">153,154</a>]. Complete healing was observed among eight Brazilian patients treated with liposomal amphotericin (total dose 35 mg/kg) with two years of follow-up [<a href="#rid155">155</a>]. Among 32 Brazilian patients treated with liposomal amphotericin (1 to 4 mg/kg/day to cumulative dose of 2500 mg) 26 were healed at a mean of 55.6 months follow-up; in the same case series 14 of 25 patients treated with pentavalent antimonial drug healed [<a href="#rid156">156</a>].</p><p><a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">Miltefosine</a> is effective for treatment of ML due to <em>L.V. braziliensis</em> in Bolivia. Among 72 patients treated with miltefosine (2.5 mg/day for 28 doses with one-year follow-up), the efficacy for mild and moderate disease was 83 and 58 percent, respectively [<a href="#rid157">157</a>]. A follow-up study extending the duration of therapy to six weeks increased the cure rate to 75 percent [<a href="#rid158">158</a>]. A case series of 40 Brazilian patients with ML showed that those with complete healing four years after treatment were 16 of 18 of those treated with miltefosine and 12 of 14 treated with meglumine antimonate [<a href="#rid146">146</a>]. </p><p>Data are limited regarding treatment of ML due to Old World species such as <em>L.L. aethiopica</em> in Sudan/Ethiopia or <em>L.L. infantum-chagasi</em> infection [<a href="#rid159">159,160</a>].</p><p>Follow-up of ML after treatment should include nasopharyngeal and laryngeal visualization every three months for one year or longer in the absence of resolution. Evidence of clinical response depends on the initial presentation; signs to follow include erythema, edema, infiltration, ulceration, and tissue destruction. Septal perforation and granulomatous-appearing lesions are common. Response is usually seen during treatment, but relapses are common. Consultation with a leishmaniasis expert should be pursued in the absence of treatment response. In some cases, surgical reconstruction may be required; if possible, tissue grafts should be delayed for at least a year after effective treatment [<a href="#rid145">145,161</a>].</p><p class="headingAnchor" id="H3151775054"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/127440.html" rel="external">"Society guideline links: Leishmaniasis"</a>.)</p><p class="headingAnchor" id="H4289568"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>There is a broad array of clinical leishmaniasis (CL) syndromes; among these, the clinical course, treatment options, response to therapy, and prognosis are all highly variable. Treatment choices are complicated by the paucity of well-controlled comparative trials and lack of standardized outcome measures. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many CL infections eventually resolve clinically without treatment, and not all patients who undergo treatment demonstrate elimination of parasitic infection. The benefits of treatment include accelerated healing of skin lesions, reduced likelihood of recurrence, diminished severity of scarring, and reduced risk for metastatic infection. (See <a class="local">'Clinical approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, we suggest local therapy for treatment of uncomplicated CL (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>); we suggest systemic therapy for treatment of complicated CL (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Features of complicated CL are summarized above. (See <a class="local">'Uncomplicated versus complicated infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapeutic agents and dosing for treatment of CL are summarized in the table  (<a class="graphic graphic_table graphicRef88693" href="/z/d/graphic/88693.html" rel="external">table 2</a>). The approach to treatment of CL is often influenced by the agents available. (See <a class="local">'Overview of therapeutic approaches'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Local therapy is preferred for treatment of uncomplicated Old World CL and may be useful for New World CL caused by species unlikely to cause disseminated infection. Cryotherapy or thermotherapy can be used for the management of patients with uncomplicated Old World or New World CL presenting with few and relatively small (≤25 mm) lesions. Topical <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> cream may be used for treatment of <strong>ulcerative</strong> lesions due to <em>L.L. major</em> or nonmucosal leishmaniasis (ML)-associated Central American species. (See <a class="local">'Local therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral systemic agents include azoles and <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a>  (<a class="graphic graphic_table graphicRef88693" href="/z/d/graphic/88693.html" rel="external">table 2</a>). In some cases, azoles can be used as first-line systemic therapy, although the efficacy of azole therapy is limited. Oral miltefosine has reasonable efficacy against many New World CL species. Data are limited regarding use of miltefosine for Old World CL, but it appears to have some efficacy. (See <a class="local">'Oral systemic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parenteral agents for treatment of CL include pentavalent antimonials, amphotericin, and <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a>  (<a class="graphic graphic_table graphicRef88693" href="/z/d/graphic/88693.html" rel="external">table 2</a>). Both pentavalent antimonials and amphotericin derivatives have activity against both Old World and New World CL. Antimonials are the historic choice for systemic parenteral therapy of CL, given observed success with antimonials and toxicity associated with use of amphotericin B; further study of liposomal amphotericin is needed. Pentamidine is used largely for treatment of infection due to <em>L.V. guyanensis</em> but is generally a secondary therapy due to its adverse effect profile. (See <a class="local">'Parenteral systemic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Healing of CL is slow and continues after the course of treatment has been completed. Treatment response is generally assessed by physical appearance. By four to six weeks following treatment, the lesion size should be decreased by approximately two-thirds, with improvement in edema and inflammation; ulcers should be reepithelializing, and new lesions should not appear. Relatively little improvement or worsening while on therapy suggests an inadequate response, and an alternate treatment approach should be planned promptly. (See <a class="local">'Clinical follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ML occurs most frequently in the New World and is characterized by mucosal destruction. Therapeutic options for treatment of ML include parenteral pentavalent antimony drugs, amphotericin B (including <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a>), and <a class="drug drug_general" data-topicid="91793" href="/z/d/drug information/91793.html" rel="external">miltefosine</a>  (<a class="graphic graphic_table graphicRef88694" href="/z/d/graphic/88694.html" rel="external">table 3</a>). The Pan American Health Organization (PAHO) recommends parenteral pentavalent antimony in combination with <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> for synergistic activity. The use of amphotericin B is somewhat limited by toxicity (lessened when liposomal amphotericin is used), though case series have demonstrated that it is associated with a better response rate and lower relapse rate than pentavalent antimony. (See <a class="local">'Mucosal leishmaniasis'</a> above.)</p><p></p><p class="headingAnchor" id="H18323583"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Dr. Karin Leder, who contributed to an earlier version of this topic review.</p><p>The content and views expressed in this publication are the sole responsibility of the author and do not necessarily reflect the views or policies of the Department of Defense or the United States government. Mention of trade names, commercial products, or organizations does not imply endorsement by the United States government.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2016; 63:e202.</a></li><li><a class="nounderline abstract_t">Pinart M, Rueda JR, Romero GA, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2020; 8:CD004834.</a></li><li><a class="nounderline abstract_t">Heras-Mosteiro J, Monge-Maillo B, Pinart M, et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2017; 12:CD005067.</a></li><li><a class="nounderline abstract_t">Sereno D. Leishmania (Mundinia) spp.: from description to emergence as new human and animal Leishmania pathogens. New Microbes New Infect 2019; 30:100540.</a></li><li class="breakAll">WHO Technical Report Series 949. “Control of the Leishmaniases.” 2010. http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf (Accessed on October 25, 2012).</li><li><a class="nounderline abstract_t">van Griensven J, Gadisa E, Aseffa A, et al. Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic Review. PLoS Negl Trop Dis 2016; 10:e0004495.</a></li><li><a class="nounderline abstract_t">Mendonça MG, de Brito ME, Rodrigues EH, et al. Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis 2004; 189:1018.</a></li><li><a class="nounderline abstract_t">Erber AC, Arana B, Bennis I, et al. An international qualitative study exploring patients' experiences of cutaneous leishmaniasis: study set-up and protocol. BMJ Open 2018; 8:e021372.</a></li><li><a class="nounderline abstract_t">Uribe-Restrepo A, Cossio A, Desai MM, et al. Interventions to treat cutaneous leishmaniasis in children: A systematic review. PLoS Negl Trop Dis 2018; 12:e0006986.</a></li><li><a class="nounderline abstract_t">Suprien C, Rocha PN, Teixeira M, et al. Clinical Presentation and Response to Therapy in Children with Cutaneous Leishmaniasis. Am J Trop Med Hyg 2020; 102:777.</a></li><li><a class="nounderline abstract_t">Unger A, O'Neal S, Machado PR, et al. Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil. Am J Trop Med Hyg 2009; 80:574.</a></li><li><a class="nounderline abstract_t">Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:528.</a></li><li><a class="nounderline abstract_t">Weigel MM, Armijos RX, Racines RJ, et al. Cutaneous leishmaniasis in subtropical Ecuador: popular perceptions, knowledge, and treatment. Bull Pan Am Health Organ 1994; 28:142.</a></li><li><a class="nounderline abstract_t">Yanik M, Gurel MS, Simsek Z, Kati M. The psychological impact of cutaneous leishmaniasis. Clin Exp Dermatol 2004; 29:464.</a></li><li><a class="nounderline abstract_t">Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg 1986; 80:859.</a></li><li><a class="nounderline abstract_t">Solomon M, Sahar N, Pavlotzky F, et al. Mucosal Leishmaniasis in Travelers with Leishmania braziliensis Complex Returning to Israel. Emerg Infect Dis 2019; 25:642.</a></li><li><a class="nounderline abstract_t">Lawn SD, Whetham J, Chiodini PL, et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM 2004; 97:781.</a></li><li><a class="nounderline abstract_t">Blum J, Lockwood DN, Visser L, et al. Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. Int Health 2012; 4:153.</a></li><li><a class="nounderline abstract_t">Hodiamont CJ, Kager PA, Bart A, et al. Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide. PLoS Negl Trop Dis 2014; 8:e2832.</a></li><li class="breakAll">Guideline for the treatment of leishmaniasis in the Americas. Pan American Health Organization. June 2022. https://www.paho.org/en/documents/guideline-treatment-leishmaniasis-americas-second-edition (Accessed on June 30, 2022).</li><li><a class="nounderline abstract_t">Copeland NK, Aronson NE. Leishmaniasis: treatment updates and clinical practice guidelines review. Curr Opin Infect Dis 2015; 28:426.</a></li><li><a class="nounderline abstract_t">Azim M, Khan SA, Ullah S, et al. Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review. PLoS Negl Trop Dis 2021; 15:e0009099.</a></li><li><a class="nounderline abstract_t">Morizot G, Kendjo E, Mouri O, et al. Travelers with cutaneous leishmaniasis cured without systemic therapy. Clin Infect Dis 2013; 57:370.</a></li><li><a class="nounderline abstract_t">Oliveira-Neto MP, Schubach A, Mattos M, et al. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am J Trop Med Hyg 1997; 57:651.</a></li><li><a class="nounderline abstract_t">Soto J, Rojas E, Guzman M, et al. Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis. Clin Infect Dis 2013; 56:1255.</a></li><li><a class="nounderline abstract_t">Shani-Adir A, Kamil S, Rozenman D, et al. Leishmania tropica in northern Israel: a clinical overview of an emerging focus. J Am Acad Dermatol 2005; 53:810.</a></li><li><a class="nounderline abstract_t">Soto J, Paz D, Rivero D, et al. Intralesional Pentamidine: A Novel Therapy for Single Lesions of Bolivian Cutaneous Leishmaniasis. Am J Trop Med Hyg 2016; 94:852.</a></li><li><a class="nounderline abstract_t">Goyonlo VM, Vosoughi E, Kiafar B, et al. Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis. Indian J Dermatol 2014; 59:631.</a></li><li><a class="nounderline abstract_t">Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS One 2017; 12:e0184777.</a></li><li><a class="nounderline abstract_t">Goldin H, Kohen S, Taxy J, et al. Leishmania tropica infection of the ear treated with photodynamic therapy. JAAD Case Rep 2020; 6:514.</a></li><li><a class="nounderline abstract_t">Solomon M, Baum S, Barzilai A, et al. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol 2007; 56:612.</a></li><li><a class="nounderline abstract_t">Solomon M, Pavlotzky F, Barzilai A, Schwartz E. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol 2013; 68:284.</a></li><li><a class="nounderline abstract_t">Machado PR, Rosa ME, Guimarães LH, et al. Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B. Clin Infect Dis 2015; 61:945.</a></li><li><a class="nounderline abstract_t">Guery R, Henry B, Martin-Blondel G, et al. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea. PLoS Negl Trop Dis 2017; 11:e0006094.</a></li><li><a class="nounderline abstract_t">Uzun S, Durdu M, Culha G, et al. Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey. J Parasitol 2004; 90:853.</a></li><li><a class="nounderline abstract_t">Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43:281.</a></li><li><a class="nounderline abstract_t">Salmanpour R, Razmavar MR, Abtahi N. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45:1115.</a></li><li><a class="nounderline abstract_t">Layegh P, Pezeshkpoor F, Soruri AH, et al. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children. Am J Trop Med Hyg 2009; 80:172.</a></li><li><a class="nounderline abstract_t">al-Majali O, Routh HB, Abuloham O, et al. A 2-year study of liquid nitrogen therapy in cutaneous leishmaniasis. Int J Dermatol 1997; 36:460.</a></li><li><a class="nounderline abstract_t">Berman JD, Neva FA. Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro. Am J Trop Med Hyg 1981; 30:318.</a></li><li><a class="nounderline abstract_t">Sadeghian G, Nilfroushzadeh MA, Iraji F. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clin Exp Dermatol 2007; 32:371.</a></li><li><a class="nounderline abstract_t">López L, Robayo M, Vargas M, Vélez ID. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials 2012; 13:58.</a></li><li><a class="nounderline abstract_t">Aronson NE, Wortmann GW, Byrne WR, et al. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis 2010; 4:e628.</a></li><li><a class="nounderline abstract_t">Reithinger R, Mohsen M, Wahid M, et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 2005; 40:1148.</a></li><li><a class="nounderline abstract_t">Solomon M, Baum S, Barzilai A, et al. Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate. J Eur Acad Dermatol Venereol 2009; 23:1189.</a></li><li><a class="nounderline abstract_t">Sharquie KE, Al-Talib KK, Chu AC. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol 1988; 119:53.</a></li><li><a class="nounderline abstract_t">Tallab TM, Bahamdam KA, Mirdad S, et al. Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int J Dermatol 1996; 35:594.</a></li><li><a class="nounderline abstract_t">Javadi A, Khamesipour A, Ghoorchi M, et al. Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial. PLoS Negl Trop Dis 2022; 16:e0010569.</a></li><li><a class="nounderline abstract_t">Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 2009; 3:e381.</a></li><li><a class="nounderline abstract_t">El-On J, Livshin R, Even-Paz Z, et al. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1986; 87:284.</a></li><li><a class="nounderline abstract_t">Ben Salah A, Zakraoui H, Zaatour A, et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995; 53:162.</a></li><li><a class="nounderline abstract_t">Asilian A, Jalayer T, Whitworth JA, et al. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995; 53:648.</a></li><li><a class="nounderline abstract_t">Soto JM, Toledo JT, Gutierrez P, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002; 66:147.</a></li><li><a class="nounderline abstract_t">Ben Salah A, Buffet PA, Morizot G, et al. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 2009; 3:e432.</a></li><li><a class="nounderline abstract_t">Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 2013; 368:524.</a></li><li><a class="nounderline abstract_t">Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 2006; 31:634.</a></li><li><a class="nounderline abstract_t">Beach DH, Goad LJ, Holz GG Jr. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol Biochem Parasitol 1988; 31:149.</a></li><li><a class="nounderline abstract_t">Salmanpour R, Handjani F, Nouhpisheh MK. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J Dermatolog Treat 2001; 12:159.</a></li><li><a class="nounderline abstract_t">Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990; 89:147.</a></li><li><a class="nounderline abstract_t">Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891.</a></li><li><a class="nounderline abstract_t">Morizot G, Delgiudice P, Caumes E, et al. Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg 2007; 76:48.</a></li><li><a class="nounderline abstract_t">Emad M, Hayati F, Fallahzadeh MK, Namazi MR. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial. J Am Acad Dermatol 2011; 64:606.</a></li><li><a class="nounderline abstract_t">Prates FV, Dourado ME, Silva SC, et al. Fluconazole in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis: A Randomized Controlled Trial. Clin Infect Dis 2017; 64:67.</a></li><li><a class="nounderline abstract_t">Francesconi VA, Francesconi F, Ramasawmy R, et al. Failure of fluconazole in treating cutaneous leishmaniasis caused by Leishmania guyanensis in the Brazilian Amazon: An open, nonrandomized phase 2 trial. PLoS Negl Trop Dis 2018; 12:e0006225.</a></li><li><a class="nounderline abstract_t">Paniz Mondolfi AE, Stavropoulos C, Gelanew T, et al. Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole. Antimicrob Agents Chemother 2011; 55:1774.</a></li><li><a class="nounderline abstract_t">Monge-Maillo B, López-Vélez R. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clin Infect Dis 2015; 60:1398.</a></li><li><a class="nounderline abstract_t">Ruiter GA, Zerp SF, Bartelink H, et al. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003; 14:167.</a></li><li><a class="nounderline abstract_t">Iranpour S, Hosseinzadeh A, Alipour A. Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis. Epidemiol Health 2019; 41:e2019011.</a></li><li><a class="nounderline abstract_t">Ware JM, O'Connell EM, Brown T, et al. Efficacy and Tolerability of Miltefosine in the Treatment of Cutaneous Leishmaniasis. Clin Infect Dis 2021; 73:e2457.</a></li><li><a class="nounderline abstract_t">Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38:1266.</a></li><li><a class="nounderline abstract_t">Rubiano LC, Miranda MC, Muvdi Arenas S, et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 2012; 205:684.</a></li><li><a class="nounderline abstract_t">Vélez I, López L, Sánchez X, et al. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83:351.</a></li><li><a class="nounderline abstract_t">Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011; 84:255.</a></li><li><a class="nounderline abstract_t">Soto J, Gutiérrez P, Soto P, et al. Treatment of Bolivian Leishmania braziliensis Cutaneous and Mucosal Leishmaniasis. Am J Trop Med Hyg 2022; 106:1182.</a></li><li><a class="nounderline abstract_t">Machado PRL, Prates FVO, Boaventura V, et al. A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil. Clin Infect Dis 2021; 73:e2465.</a></li><li><a class="nounderline abstract_t">Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 78:210.</a></li><li><a class="nounderline abstract_t">Machado PR, Ampuero J, Guimarães LH, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2010; 4:e912.</a></li><li><a class="nounderline abstract_t">Mohebali M, Fotouhi A, Hooshmand B, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007; 103:33.</a></li><li><a class="nounderline abstract_t">van Thiel PP, Leenstra T, Kager PA, et al. Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis 2010; 50:80.</a></li><li><a class="nounderline abstract_t">Mosimann V, Blazek C, Grob H, et al. Miltefosine for Mucosal and Complicated Cutaneous Old World Leishmaniasis: A Case Series and Review of the Literature. Open Forum Infect Dis 2016; 3:ofw008.</a></li><li><a class="nounderline abstract_t">van Henten S, Tesfaye AB, Abdela SG, et al. Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia. PLoS Negl Trop Dis 2021; 15:e0009460.</a></li><li><a class="nounderline abstract_t">Dorlo TP, van Thiel PP, Huitema AD, et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008; 52:2855.</a></li><li><a class="nounderline abstract_t">Dorlo TP, van Thiel PP, Schoone GJ, et al. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLoS Negl Trop Dis 2011; 5:e1436.</a></li><li><a class="nounderline abstract_t">Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 2012; 67:2576.</a></li><li><a class="nounderline abstract_t">Saurabh S, Mahabir M. Adverse ocular events on miltefosine treatment for post-kala-azar dermal leishmaniasis in India. Trop Doct 2020; 50:37.</a></li><li><a class="nounderline abstract_t">Kusumesh R, Ambasta A, Arya LK, et al. Keratitis occurring in patients treated with miltefosine for post-kala-azar dermal leishmaniasis. Br J Ophthalmol 2021; 105:1497.</a></li><li><a class="nounderline abstract_t">Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100 Suppl 1:S17.</a></li><li><a class="nounderline abstract_t">Dorlo TP, Balasegaram M, Lima MA, et al. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. J Antimicrob Chemother 2012; 67:1996.</a></li><li><a class="nounderline abstract_t">Moore E, O'Flaherty D, Heuvelmans H, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 2001; 79:388.</a></li><li><a class="nounderline abstract_t">Ritmeijer K, Veeken H, Melaku Y, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95:668.</a></li><li><a class="nounderline abstract_t">Berman JD, Gallalee JV, Best JM. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem Pharmacol 1987; 36:197.</a></li><li><a class="nounderline abstract_t">Pathak MK, Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol 2001; 167:3391.</a></li><li><a class="nounderline abstract_t">Soto J, Valda-Rodriquez L, Toledo J, et al. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am J Trop Med Hyg 2004; 71:577.</a></li><li><a class="nounderline abstract_t">Sáenz RE, Paz HM, Johnson CM, et al. [Evaluation of the effectiveness and toxicity of pentostam and glucantime in the treatment of cutaneous leishmaniasis]. Rev Med Panama 1987; 12:148.</a></li><li><a class="nounderline abstract_t">Deps PD, Viana MC, Falqueto A, Dietze R. [Comparative assessment of the efficacy and toxicity of N-methyl-glucamine and BP88 sodium stibogluconate in the treatment of localized cutaneous leishmaniasis]. Rev Soc Bras Med Trop 2000; 33:535.</a></li><li><a class="nounderline abstract_t">Saldanha AC, Romero GA, Guerra C, et al. [Comparative study between sodium stibogluconate BP 88 and meglumine antimoniate in cutaneous leishmaniasis treatment. II. Biochemical and cardiac toxicity]. Rev Soc Bras Med Trop 2000; 33:383.</a></li><li><a class="nounderline abstract_t">Velez I, Agudelo S, Hendrickx E, et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 1997; 126:232.</a></li><li><a class="nounderline abstract_t">Tuon FF, Amato VS, Graf ME, et al. Treatment of New World cutaneous leishmaniasis--a systematic review with a meta-analysis. Int J Dermatol 2008; 47:109.</a></li><li><a class="nounderline abstract_t">Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 2007; 57:335.e1.</a></li><li><a class="nounderline abstract_t">Sadeghian G, Nilforoushzadeh MA. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45:819.</a></li><li><a class="nounderline abstract_t">Cruz A, Rainey PM, Herwaldt BL, et al. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis 2007; 195:602.</a></li><li><a class="nounderline abstract_t">Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 2001; 64:187.</a></li><li><a class="nounderline abstract_t">Aronson NE, Wortmann GW, Johnson SC, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis 1998; 27:1457.</a></li><li><a class="nounderline abstract_t">Oliveira LF, Schubach AO, Martins MM, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop 2011; 118:87.</a></li><li><a class="nounderline abstract_t">Gasser RA Jr, Magill AJ, Oster CN, et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18:83.</a></li><li><a class="nounderline abstract_t">Lawn SD, Armstrong M, Chilton D, Whitty CJ. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg 2006; 100:264.</a></li><li><a class="nounderline abstract_t">Wise ES, Armstrong MS, Watson J, Lockwood DN. Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected]. PLoS Negl Trop Dis 2012; 6:e1688.</a></li><li><a class="nounderline abstract_t">Wortmann GW, Aronson NE, Byrd JC, et al. Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis. Clin Infect Dis 1998; 27:509.</a></li><li><a class="nounderline abstract_t">McBride MO, Linney M, Davidson RN, Weber JN. Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate. Clin Infect Dis 1995; 21:710.</a></li><li><a class="nounderline abstract_t">Mueller M, Balasegaram M, Koummuki Y, et al. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother 2006; 58:811.</a></li><li><a class="nounderline abstract_t">Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother 2005; 55:229.</a></li><li><a class="nounderline abstract_t">Ashutosh, Sundar S, Goyal N. Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 2007; 56:143.</a></li><li><a class="nounderline abstract_t">Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 2008; 46:223.</a></li><li><a class="nounderline abstract_t">O'Neal SE, Guimarães LH, Machado PR, et al. Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis. J Infect Dis 2007; 195:142.</a></li><li><a class="nounderline abstract_t">Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother 1990; 34:183.</a></li><li><a class="nounderline abstract_t">Amato VS, Tuon FF, Imamura R, et al. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol 2009; 23:1026.</a></li><li><a class="nounderline abstract_t">Rocio C, Amato VS, Camargo RA, et al. Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients. Trans R Soc Trop Med Hyg 2014; 108:176.</a></li><li><a class="nounderline abstract_t">Cunha MA, Leão AC, de Cassia Soler R, Lindoso JA. Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study. Am J Trop Med Hyg 2015; 93:1214.</a></li><li><a class="nounderline abstract_t">Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000; 13:243.</a></li><li><a class="nounderline abstract_t">Wortmann GW, Fraser SL, Aronson NE, et al. Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis. Clin Infect Dis 1998; 26:1006.</a></li><li><a class="nounderline abstract_t">Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991; 40:302.</a></li><li><a class="nounderline abstract_t">Maheshwari A, Seth A, Kaur S, et al. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar. Pediatr Infect Dis J 2011; 30:180.</a></li><li><a class="nounderline abstract_t">Thakur CP. Sodium antimony gluconate, amphotericin, and myocardial damage. Lancet 1998; 351:1928.</a></li><li><a class="nounderline abstract_t">Wortmann G, Zapor M, Ressner R, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83:1028.</a></li><li><a class="nounderline abstract_t">Townsend RW, Zutshi A, Bekersky I. Biodistribution of 4-[(14)C]cholesterol-AmBisome following a single intravenous administration to rats. Drug Metab Dispos 2001; 29:681.</a></li><li><a class="nounderline abstract_t">Neves LO, Talhari AC, Gadelha EP, et al. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An Bras Dermatol 2011; 86:1092.</a></li><li><a class="nounderline abstract_t">Motta JO, Sampaio RN. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2012; 26:331.</a></li><li><a class="nounderline abstract_t">Solomon M, Pavlotsky F, Leshem E, et al. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol 2011; 25:973.</a></li><li><a class="nounderline abstract_t">Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010; 8:419.</a></li><li><a class="nounderline abstract_t">Hellier I, Dereure O, Tournillac I, et al. Treatment of Old World cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients. Dermatology 2000; 200:120.</a></li><li><a class="nounderline abstract_t">Jauréguiberry S, Graby G, Caumes E. Efficacy of short-course intramuscular pentamidine isethionate treatment on Old World localized cutaneous leishmaniasis in 2 patients. Clin Infect Dis 2006; 42:1812.</a></li><li><a class="nounderline abstract_t">Low-A-Chee RM, Rose P, Ridley DS. An outbreak of cutaneous leishmaniasis in Guyana: epidemiology, clinical and laboratory aspects. Ann Trop Med Parasitol 1983; 77:255.</a></li><li><a class="nounderline abstract_t">Pradinaud R, et al. Bilan de 10 annees de traitement de la leishmaniose tegumentaire par la pentamidine en Guyane Francaise: a propos de 1025 cas. Nouv Dermatol 1991; 10:456.</a></li><li><a class="nounderline abstract_t">Lightburn E, Morand JJ, Meynard JB, et al. [Management of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate]. Med Trop (Mars) 2003; 63:35.</a></li><li><a class="nounderline abstract_t">Lai A Fat EJ, Vrede MA, Soetosenojo RM, Lai A Fat RF. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol 2002; 41:796.</a></li><li><a class="nounderline abstract_t">van der Meide WF, Sabajo LO, Jensema AJ, et al. Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname. Int J Dermatol 2009; 48:52.</a></li><li><a class="nounderline abstract_t">Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, et al. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 2005; 72:133.</a></li><li><a class="nounderline abstract_t">Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993; 16:417.</a></li><li><a class="nounderline abstract_t">Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 1994; 50:107.</a></li><li><a class="nounderline abstract_t">Gadelha EPN, Ramasawmy R, da Costa Oliveira B, et al. An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region. PLoS Negl Trop Dis 2018; 12:e0006850.</a></li><li><a class="nounderline abstract_t">Christen JR, Bourreau E, Demar M, et al. Use of the intramuscular route to administer pentamidine isethionate in Leishmania guyanensis cutaneous leishmaniasis increases the risk of treatment failure. Travel Med Infect Dis 2018; 24:31.</a></li><li><a class="nounderline abstract_t">Murray HW. Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg 2012; 86:434.</a></li><li><a class="nounderline abstract_t">Sakthianandeswaren A, Elso CM, Simpson K, et al. The wound repair response controls outcome to cutaneous leishmaniasis. Proc Natl Acad Sci U S A 2005; 102:15551.</a></li><li><a class="nounderline abstract_t">Khatami A, Talaee R, Rahshenas M, et al. Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial. PLoS One 2013; 8:e66123.</a></li><li><a class="nounderline abstract_t">Wortmann GW, Aronson NE, Miller RS, et al. Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis 2000; 31:199.</a></li><li><a class="nounderline abstract_t">Sampaio RNR, Silva JSFE, Paula CDR, et al. A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis. Rev Soc Bras Med Trop 2019; 52:e20180292.</a></li><li><a class="nounderline abstract_t">Machado PR, Lessa H, Lessa M, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007; 44:788.</a></li><li><a class="nounderline abstract_t">Saenz RE, de Rodriguez CG, Johnson CM, Berman JD. Efficacy and toxicity of pentostam against Panamanian mucosal leishmaniasis. Am J Trop Med Hyg 1991; 44:394.</a></li><li><a class="nounderline abstract_t">Franke ED, Wignall FS, Cruz ME, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 1990; 113:934.</a></li><li><a class="nounderline abstract_t">Franke ED, Llanos-Cuentas A, Echevarria J, et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 1994; 51:77.</a></li><li><a class="nounderline abstract_t">Amato V, Amato J, Nicodemo A, et al. [Treatment of mucocutaneous leishmaniasis with pentamidine isothionate]. Ann Dermatol Venereol 1998; 125:492.</a></li><li><a class="nounderline abstract_t">Amato VS, Tuon FF, Siqueira AM, et al. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg 2007; 77:266.</a></li><li><a class="nounderline abstract_t">Sampaio SA, Castro RM, Dillon NL, Martins JE. Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: report of 70 cases. Int J Dermatol 1971; 10:179.</a></li><li><a class="nounderline abstract_t">Rodriguez LV, Dedet JP, Paredes V, et al. A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis. Mem Inst Oswaldo Cruz 1995; 90:525.</a></li><li><a class="nounderline abstract_t">Amato VS, Tuon FF, Camargo RA, et al. Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 2011; 85:818.</a></li><li><a class="nounderline abstract_t">Santos CR, Tuon FF, Cieslinski J, et al. Comparative study on liposomal amphotericin B and other therapies in the treatment of mucosal leishmaniasis: A 15-year retrospective cohort study. PLoS One 2019; 14:e0218786.</a></li><li><a class="nounderline abstract_t">Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007; 44:350.</a></li><li><a class="nounderline abstract_t">Soto J, Rea J, Valderrama M, et al. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg 2009; 81:387.</a></li><li><a class="nounderline abstract_t">el-Hassan AM, Meredith SE, Yagi HI, et al. Sudanese mucosal leishmaniasis: epidemiology, clinical features, diagnosis, immune responses and treatment. Trans R Soc Trop Med Hyg 1995; 89:647.</a></li><li><a class="nounderline abstract_t">Aliaga L, Cobo F, Mediavilla JD, et al. Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and microbiologic findings in 31 patients. Medicine (Baltimore) 2003; 82:147.</a></li><li class="breakAll">Jeronimo SMB, de Queiroz Sousa A, Pearson RD. Leishmaniasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant RL, Walker DH, Weller PF (Eds), Saunders Elsevier, Philadelphia 2011. p.696.</li></ol></div><div id="topicVersionRevision">Topic 5686 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941151" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32853410" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Interventions for American cutaneous and mucocutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29192424" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Interventions for Old World cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31061710" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Leishmania (Mundinia) spp.: from description to emergence as new human and animal Leishmania pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31061710" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Leishmania (Mundinia) spp.: from description to emergence as new human and animal Leishmania pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26938448" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999605" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29909372" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : An international qualitative study exploring patients' experiences of cutaneous leishmaniasis: study set-up and protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30550538" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Interventions to treat cutaneous leishmaniasis in children: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32043440" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical Presentation and Response to Therapy in Children with Cutaneous Leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19346378" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1311351" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8069334" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cutaneous leishmaniasis in subtropical Ecuador: popular perceptions, knowledge, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15347324" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The psychological impact of cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3037735" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mucosal leishmaniasis ("espundia" Escomel, 1911).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30882319" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mucosal Leishmaniasis in Travelers with Leishmania braziliensis Complex Returning to Israel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569809" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24029394" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24787001" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24787001" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26312442" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Leishmaniasis: treatment updates and clinical practice guidelines review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33657097" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633111" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Travelers with cutaneous leishmaniasis cured without systemic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9430521" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23390069" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16243129" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Leishmania tropica in northern Israel: a clinical overview of an emerging focus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26903605" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intralesional Pentamidine: A Novel Therapy for Single Lesions of Bolivian Cutaneous Leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25484415" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28926630" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32490113" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Leishmania tropica infection of the ear treated with photodynamic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276541" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22858005" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26048961" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29155816" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15357081" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15090013" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16961529" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19190206" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9248896" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A 2-year study of liquid nitrogen therapy in cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7235124" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17376205" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22594858" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231896" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15791515" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19298486" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2841964" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8854166" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35802749" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19221595" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3734476" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Topical treatment of cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7677218" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8561269" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12135285" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19415122" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23388004" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Topical paromomycin with or without gentamicin for cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16780497" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2847043" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12243707" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2166429" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11907288" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17255228" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21315963" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27803094" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fluconazole in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29481560" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Failure of fluconazole in treating cutaneous leishmaniasis caused by Leishmania guyanensis in the Brazilian Amazon: An open, nonrandomized phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21282455" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25601455" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12569304" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30999735" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33124666" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy and Tolerability of Miltefosine in the Treatment of Cutaneous Leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127339" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Miltefosine for new world cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22238470" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20682881" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292895" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35385826" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Treatment of Bolivian Leishmania braziliensis Cutaneous and Mucosal Leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32894278" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18256415" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21200420" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17586452" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19951107" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27042675" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Miltefosine for Mucosal and Complicated Cutaneous Old World Leishmaniasis: A Case Series and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34048461" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18519729" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22180803" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22833634" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31610724" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Adverse ocular events on miltefosine treatment for post-kala-azar dermal leishmaniasis in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32962993" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Keratitis occurring in patients treated with miltefosine for post-kala-azar dermal leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16730362" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Development of miltefosine as an oral treatment for leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22577099" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11417033" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11816442" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3028425" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11544330" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569787" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2827242" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : [Evaluation of the effectiveness and toxicity of pentostam and glucantime in the treatment of cutaneous leishmaniasis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11175583" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : [Comparative assessment of the efficacy and toxicity of N-methyl-glucamine and BP88 sodium stibogluconate in the treatment of localized cutaneous leishmaniasis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10936953" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : [Comparative study between sodium stibogluconate BP 88 and meglumine antimoniate in cutaneous leishmaniasis treatment. II. Biochemical and cardiac toxicity].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9027276" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18211479" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Treatment of New World cutaneous leishmaniasis--a systematic review with a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17337090" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16863518" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17230422" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11442216" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9868660" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21420925" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7519887" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16289167" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22745840" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9770149" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8527590" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16916865" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15649998" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17244793" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Molecular mechanisms of antimony resistance in Leishmania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18171254" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17152018" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2183713" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Amphotericin B: current understanding of mechanisms of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453817" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24535153" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26483120" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10755238" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9564500" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1942779" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Effect of salt supplementation on amphotericin B nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823781" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9654264" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Sodium antimony gluconate, amphotericin, and myocardial damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21036832" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11302934" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Biodistribution of 4-[(14)C]cholesterol-AmBisome following a single intravenous administration to rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22281895" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21492255" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21129042" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20377337" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10773699" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Treatment of Old World cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16705598" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Efficacy of short-course intramuscular pentamidine isethionate treatment on Old World localized cutaneous leishmaniasis in 2 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6625725" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : An outbreak of cutaneous leishmaniasis in Guyana: epidemiology, clinical and laboratory aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Bilan de 10 annees de traitement de la leishmaniose tegumentaire par la pentamidine en Guyane Francaise: a propos de 1025 cas</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12891748" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : [Management of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12453009" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19126051" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741547" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8384011" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8304565" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30379814" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29482012" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Use of the intramuscular route to administer pentamidine isethionate in Leishmania guyanensis cutaneous leishmaniasis increases the risk of treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22403313" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Leishmaniasis in the United States: treatment in 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16223880" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : The wound repair response controls outcome to cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23826087" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10913426" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Cutaneous leishmaniasis following local trauma: a clinical pearl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30942258" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17304449" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1645930" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Efficacy and toxicity of pentostam against Panamanian mucosal leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2173461" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8059918" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9747313" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : [Treatment of mucocutaneous leishmaniasis with pentamidine isothionate].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17690398" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Treatment of mucosal leishmaniasis in Latin America: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5116171" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: report of 70 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8551959" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22049033" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31242231" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Comparative study on liposomal amphotericin B and other therapies in the treatment of mucosal leishmaniasis: A 15-year retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205440" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Treatment of Bolivian mucosal leishmaniasis with miltefosine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706901" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8594683" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Sudanese mucosal leishmaniasis: epidemiology, clinical features, diagnosis, immune responses and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12792301" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and microbiologic findings in 31 patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
